Investor Relations

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.

CR-000172

News Release

 View printer-friendly version

Charles River Selected to Host Association of Clinical Pharmacology Units' Annual Conference

Marks Historic First in Conference History for an Independent Clinical Pharmacology Unit to Host the Meeting

WILMINGTON, Mass.--(BUSINESS WIRE)--The Association of Clinical Pharmacology Units (ACPU), for the first time in its history, selected an independent CPU as the host for its 2008 Annual Meeting. Charles River Laboratories International, Inc.'s (NYSE:CRL) Tacoma, Washington clinical services facility is hosting the event, themed "Taking Aim at Moving Targets of Phase I," which will focus on evolving industry dynamics. Conference attendees will identify practical strategies for overcoming Phase I study challenges that can be adopted within their organizations.

"As we focus on Phase I transformations, Charles River's clinical services embody the evolution occurring in our industry. The Company's state-of-the-art facilities, expert staff, and broad range of services exemplifies the progress in Phase I studies," said Dr. Michael A. Turik, ACPU President. "This is a historic year for our annual meeting. For the first time in 18 years, we are hosting the event at an independent CPU."

The three-day conference will explore issues including regulatory requirements, disaster recovery, safety and adverse events as well as best practices. Speakers include regulatory agency experts as well as executives from Abbott Laboratories, Amgen Inc., Lilly Center for Medical Sciences and Charles River. The conference is scheduled for October 20 - 22, 2008 and will take place at the Hotel Murano in Tacoma, Washington. Additional information on the event including the complete agenda can be found at: http://acpu.net/2008-annual-meeting/

"We are thrilled to host this collaboration and sharing of industry best practices," said Dr. Royce Morrison, Clinic Strategist at Charles River and Conference Chairperson. "We share the collective goals of safely accelerating drug development and increasing the value of early-phase research, as it becomes more complex. This event brings us together to teach, learn, inspire and challenge each other."

About the ACPU

The mission of the ACPU shall be to provide a forum facilitating cooperation and the exchange of information and ideas between Clinical Pharmacology Units. Objectives encompassed within this mission include without limitation: Provide the opportunity for individual disciplines involved in clinical pharmacology studies to meet and discuss issues common to their practices. Facilitate the formation of scientific, technical and methodological foundations for the state-of- the-art drug evaluations. Promote the establishment of voluntary minimum standards of practice and guidelines for clinical pharmacology units. Foster the continuing education of its membership through the provision of appropriate educational opportunities.

About Charles River

Accelerating Drug Development. Exactly. Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies, and leading academic institutions around the globe accelerate their research and drug development efforts. Our more than 9,000 employees worldwide are focused on providing clients with exactly what they need to improve and expedite the discovery, development through first-in-human evaluation, and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

Source: Charles River Laboratories International, Inc.

Featured Report

2018 Annual Report (PDF)

Investor Hotline

877-567-6CRL (6275)